{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-082994","form_type":"8-K","ticker":null,"cik":"0001008848","company_name":"Acorda Therapeutics, Inc.","filed_at":"2024-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.862006+00:00","generated_at":"2026-05-31T21:39:51.570612+00:00","sec_items":["2.01","9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Acorda Therapeutics completes $185M asset sale to Merz, no stockholder recovery","bullets":["On July 10, 2024, Acorda completed the sale of substantially all assets to Merz Pharmaceuticals for $185 million, as part of its Chapter 11 proceedings.","Approximately $139 million of the proceeds were distributed to secured creditors, including $62 million to repay the debtor-in-possession loan.","No proceeds are expected for common stockholders; the company's stock will be cancelled upon effectiveness of the liquidation plan.","The company anticipates deregistering its common stock after Court confirmation of the plan; trading is highly speculative."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-082994","json":"https://secwatch.observer/filing/0000950170-24-082994.json","markdown":"https://secwatch.observer/filing/0000950170-24-082994.md","text":"https://secwatch.observer/filing/0000950170-24-082994.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1008848/000095017024082994/0000950170-24-082994-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1008848/000095017024082994/acor-20240710.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T21:39:51.570612+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aea79856ec433ee5957ba4d8b0836b35fd483ddf","claim":"Acorda Therapeutics, Inc. completed a disposition involving Merz Pharmaceuticals, LLC for $185.0 million (closed 2024-07-10).","evidence_excerpt":"payment obligations thereunder, Merz Pharma GmbH & Co. KGaA. The Asset Purchase Agreement provides for the sale of substantially all of the Company’s assets to the Purchaser for $185.0 million, less certain deductions and adjustments as specified in the Asset Purchase Agreement (the “Asset Sale”). On April 1, 2024, the Company, together with certain of its subsidiaries","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1008848/000095017024082994/0000950170-24-082994-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Merz Pharmaceuticals, LLC"},{"label":"Consideration","value":"$185.0 million"},{"label":"Closing","value":"2024-07-10"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}